Antibody targeting of VEGF/VEGFR2 signaling increases the efficacy of adoptive T-cell therapy of established B16 melanomas [36] and has been demonstrated to enhance the antitumor effect of agonistic CD40-antibodies after subcutaneous injection of RM-1 prostate cancer cells [37]. This evidence concerns the gene VEGFA and prostate carcinoma.